je.st
news
Tag: merck
Merck completes sale of consumer unit to Bayer
2014-10-01 22:56:52| Biotech - Topix.net
Drugmaker Merck said Wednesday that it completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 billion. Bayer AG agreed to buy the business in May. Merck, of Whitehouse Station, New Jersey, said it expects about $9 billion in proceeds after taxes.
Tags: sale
unit
consumer
bayer
Merck completes sale of consumer unit to Bayer
2014-10-01 22:16:41| Chemicals - Topix.net
Drugmaker Merck said Wednesday that it completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 billion. Bayer AG agreed to buy the business in May. Merck, of Whitehouse Station, New Jersey, said it expects about $9 billion in proceeds after taxes.
Tags: sale
unit
consumer
bayer
Merck Completes Sale of Consumer Care Business to Bayer AG for $14.2 Billion
2014-10-01 17:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Worldwide Collaboration to Market and Develop Portfolio of Soluble Guanylate Cyclase (sGC) Modulators Commences WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today it has completed the previously announced sale of the Merck Consumer Care (MCC) business to Bayer AG. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Steve Cragle, 908-423-3461Investor:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: business
care
sale
consumer
Germanys Merck Agrees To Buy Sigma-Aldrich
2014-10-01 07:29:00| Chemical Processing
Germanys Merck KGaA is purchasing Sigma-Aldrich for $17 billion.
Tags: buy
agrees
merck
germanys
Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014
2014-09-29 11:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. KEYTRUDA monotherapy achieved 24 percent overall response rate in patients with PD-L1 positive, advanced bladder (urothelial) cancer Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA (pembrolizumab) the companys anti-PD-1 therapy in PD-L1 positive, advanced urothelial cancer (also known as bladder cancer). Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
data
advanced
early
Sites : [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] next »